Table 3.
Statistical association between ISG15 protein expression and clinicopathological characteristics of the studies cohort
| Parameters | ISG15 protein expression | ||
|---|---|---|---|
| Low | High | p value | |
| N (%) | N (%) | ||
| Tumour size | |||
| ≤ 2.0 cm | 144 (45) | 178 (55) | 0.044 |
| > 2.0 cm | 127 (37) | 216 (63) | |
| Nodal status | |||
| Negative | 393 (52) | 369 (48) | 0.192 |
| Positive | 165 (43) | 219 (57) | |
| Histological grade | |||
| 1 | 43 (51) | 42 (49) | 0.002 |
| 2 | 104 (47) | 117 (53) | |
| 3 | 128 (35) | 238 (65) | |
| Tumour histological subtypes | |||
| Ductal (NST) | 216 (39) | 336 (71) | 0.003 |
| Lobular | 43 (61) | 28 (39) | |
| Medullary-like | 11 (79) | 3 (21) | |
| Special type | 10 (37) | 17 (63) | |
| Lymphovascular invasion | |||
| Negative | 164 (44) | 210 (56) | < 0.001 |
| Positive | 62 (30) | 144 (70) | |
| Nottingham prognostic index | |||
| Good prognostic group | 91 (51) | 88 (49) | 0.005 |
| Moderate prognostic group | 134 (38) | 220 (62) | |
| Poor prognostic group | 46 (35) | 86 (65) | |
| Age | |||
| ≤ 50 | 92 (36) | 163 (64) | 0.034 |
| > 50 | 179 (44) | 232 (56) | |
| Oestrogen receptor | |||
| Negative | 49 (30) | 133 (73) | < 0.001 |
| Positive | 222 (46) | 263 (54) | |
| Progesterone receptor | |||
| Negative | 97 (34) | 186 (66) | 0.008 |
| Positive | 165 (45) | 205 (55) | |
| Human epidermal growth factor receptor 2 | |||
| Negative | 243 (44) | 313 (56) | |
| < 0.001 | |||
| Positive | 19 (21) | 73 (79) | |
| P53 | |||
| Negative | 201 (45) | 250 (55) | 0.001 |
| Positive | 58 (29) | 141 (71) | |
| Ki67 | |||
| Negative | 95(46) | 111 (54) | 0.008 |
| Positive | 120 (35) | 226 (65) | |
| E-Cadherin | |||
| Negative | 109 (36) | 268 (64) | 0.005 |
| Positive | 109 (48) | 120 (52) | |
| N-Cadherin | |||
| Negative | 52 (38) | 84 (62) | 0.904 |
| Positive | 151 (39) | 238 (61) | |
| Basal-phenotype | |||
| Negative | 361 (79) | 96 (21) | 0.010 |
| Positive | 246 (71) | 102 (29) | |
| Epithelial growth factor receptor | |||
| Negative | 222 (43) | 298 (57) | 0.03 |
| Positive | 43 (32) | 90 (68) | |
| CD8 | |||
| Negative | 116 (44) | 147 (56) | 0.013 |
| Positive | 84 (33) | 167 (67) | |
| CD44 | |||
| Negative | 76 (43) | 100 (57) | 0.005 |
| Positive | 44 (28) | 72 (72) | |
| FOXP3 | |||
| Negative | 86 (47) | 99 (53) | 0.019 |
| Positive | 125 (36) | 222 (64) | |
| CD68 | |||
| Negative | 85 (47) | 96 (53) | 0.008 |
| Positive | 114 (35) | 212 (65) | |
| IHC subtypes | |||
| Luminal A | 100(45) | 124 (55) | < 0.001 |
| Luminal B | 50 (33) | 100 (67) | |
| Her2 enriched | 26 (20) | 103 (80) | |
| TNBC | 19 (21) | 73 (79) | |
Significant correlations are in bold